With the rapid development of "Internet plus", medical care has entered the era of big data. However, there is little research on medical big data (MBD) from the perspectives of bibliometrics and visualization. The substantive research on the basic aspects of MBD itself is also rare. This study aims to explore the current status of medical big data through visualization analysis on the journal papers related to MBD. We analyze a total of 988 references which were downloaded from the Science Citation Index Expanded and the Social Science Citation Index databases from Web of Science and the time span was defined as "all years". The GraphPad Prism 5, VOSviewer and CiteSpace softwares are used for analysis. Many results concerning the annual trends, the top players in terms of journal and institute levels, the citations and H-index in terms of country level, the keywords distribution, the highly cited papers, the co-authorship status and the most influential journals and authors are presented in this paper. This study points out the development status and trends on MBD. It can help people in the medical profession to get comprehensive understanding on the state of the art of MBD. It also has reference values for the research and application of the MBD visualization methods.

No abstract

No abstract

No abstract

Recently, B7-H3 was frequently reported to be overexpressed in various cancer types and has been suggested to be a promising target for cancer immunotherapy. In the present study, we analyzed the mRNA expression of B7-H3 in The Cancer Genome Atlas (TCGA) database and validated its expression across multiple cancer types. We then generated a novel B7-H3-targeted chimeric antigen receptor (CAR) and tested its antitumor activity both in vitro and in vivo. The B7-H3 expression heterogeneity and variation were frequent. Moderate or even high expression levels of B7-H3 were also observed in some tumor-adjacent tissues, but the staining intensity was weaker than that in tumor tissues. B7-H3 expression was absent or very low in normal tissues and organs. Flow cytometry indicated that the mean expression level of B7-H3 in eight bone marrow specimens from patients with acute myeloid leukemia (AML) was 57.2% (range 38.8-80.4). Furthermore, we showed that the B7-H3-targeted CAR-T cells exhibited significant antitumor activity against AML and melanoma in vitro and in xenograft mouse models. In conclusion, although B7-H3 represents a promising pan-cancer target, and B7-H3-redirected CAR-T cells can effectively control tumor growth, the expression heterogeneity and variation have to be carefully considered in translating B7-H3-targeted CAR-T cell therapy into clinical practice.

No abstract

No abstract

No abstract